Tantai, Narisa <br/><br/>
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.  [electronic resource] 

 -  BMC health services research  Apr 2014 
 - 170 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1472-6963 
<br/><br/><label>Standard No.: </label>10.1186/1472-6963-14-170  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adult<br/>Antiviral Agents--economics<br/>Cost-Benefit Analysis<br/>Drugs, Essential--economics<br/>Female<br/>Health Services Research<br/>Hepatitis B e Antigens<br/>Hepatitis B, Chronic--drug therapy<br/>Humans<br/>Lamivudine--economics<br/>Male<br/>Markov Chains<br/>Models, Economic<br/>Organophosphonates--economics<br/>Quality-Adjusted Life Years<br/>Tenofovir<br/>Thailand--epidemiology<br/>Treatment Outcome